2026-07-21T07:17:45Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/128212025-04-10T09:11:53Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16938col_20.500.12105_16963

00925njm 22002777a 4500 dc Pérez-Valero, I author González-Baeza, A author Estébanez, M author Montes, M author Bayon, C author Pulido, F author Cambrón, I author Bernardino, J author Zamora, F author Monge Corella, Susana author Gaya, F author Lagarde, M author Rubio, R author Hernando, A author González-García, Juan author Arnalich, F author Arribas, José R author 2012-11 J Int AIDS Soc. 2012 Nov 11;15 Suppl 4(Suppl 4):18179. 10.7448/IAS.15.6.18179 1758-2652 Journal of the International AIDS Society http://hdl.handle.net/20.500.12105/12821 Prolonged treatment with boosted protease inhibitor monotherapy is not associated with a higher rate of neurocognitive impairment than triple drug ART